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ABSTRACT
Objective: To evaluate survival and recurrence in stage II endometrial cancer in relation 
to uterine risk stratification. Outcome for stage II was compared before and after the 
introduction of lymph node (LN) resection and omission of all postoperative radiotherapy.
Methods: The cohort consisted of 4,380 endometrial carcinoma patients radically operated 
(no visual tumor, all distant metastasis removed) (2005–2012) including 461 stage II. 
Adjusted Cox regression was used to compare survival and actuarial recurrence rates.
Results: Uterine risk factors (low-, intermediate-, and high-) were the strongest predictors of 
survival and recurrence in stage II. Stage II low-risk having a prognosis comparable to low-risk 
stage I (grade 1–2, <50% myometrial invasion), whereas cervical invasion significantly increased 
the risk of recurrence and decreased cancer-specific survival in intermediate- and high-risk 
compared to the corresponding stage I risk groups. In 355 cases of 708 with cervical stromal 
invasion, LN-resection showed 27.9% with LN metastasis and upstaged 18.1% from stage II 
to IIIC resulting in longer survival and lower recurrence in LN-resected compared to non-LN 
resected stage II. Radical as compared to simple hysterectomy did not alter survival. Treatment 
with external beam radiotherapy decreased local recurrence without affecting survival.
Conclusion: Uterine risk groups are the strongest predictors for survival and recurrence in 
stage II patients and should be considered when advising adjuvant therapy. LN-resected stage 
II had increased survival and decreased recurrence. Omitting radiotherapy increase vaginal 
recurrence without affecting survival.
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INTRODUCTION
Stage II endometrial cancer patients are a heterogeneous group with the common feature of 
cervical stromal invasion but otherwise different characteristics (grade, superficial or deep 
myometrial invasion), and both endometrioid and non-endometrioid tumors are included.
Management of stage II disease is therefore controversial with respect to both surgery 
and postoperative treatment. Lymph node (LN) staging of pelvic and paraaortic LNs is 
recommended [1]. Cervical stromal invasion may be identified by magnetic resonance 
imaging (MRI) preoperatively with a sensitivity of 80%, but is otherwise difficult to recognize 
before or during surgery [2-5]. It is therefore important to determine whether reoperation 
is necessary in case of undiscovered cervical stromal invasion, especially in the presence 
of low-risk uterine characteristics (stage II with grade 1 and 2 with <50% myometrial 
invasion). Radical hysterectomy is used to ensure radical borders in cases with parametrial 
invasion, but cervical stromal invasion does not seem to predict parametrial invasion [6], 
and radical hysterectomy does not seem to increase survival [7,8] and is therefore no longer 
recommended [1]. Omentectomy is only recommended in case of serous histology.
The European guidelines recommend brachytherapy for LN-resected stage II patients with 
grade 1 and 2 tumors, brachytherapy or external beam radiotherapy (EBRT) for grade 3, EBRT 
for non-staged, and adjuvant chemotherapy for serous histology [1]. In a previous Danish 
national study, 29% of International Federation of Gynaecology and Obstetrics (FIGO) 88 
stage II cases recurred within the first 14 years after surgery and 16.4% recurring outside the 
field where radiation traditionally would have been delivered, indicating that some type of 
systemic adjuvant therapy may be needed [9].
The Danish national guidelines introduced pelvic LN resection for stage II cases in 2005 and 
omitted EBRT in 2010, and according to the present and past guidelines, no patients are 
recommended brachytherapy. Patients are instead offered postoperative adjuvant chemotherapy 
in the ongoing ENGOT-EN2-DGCG/EORTC-55102 trial [10]. The identification of more specific 
prognostic factors in this heterogeneous group of patients with only cervical stromal invasion 
in common may help tailor both surgical and adjuvant therapy and thereby reduce the very high 
recurrence rates demonstrated in Danish stage II endometrial cancer patients [9].
Applying the same risk stratification in stage II cases as were applied in stage I cases could 
be valuable to determine whether survival, risk and type of recurrence including risk of LN 
metastasis are dependent on cervical stromal invasion.
Our aim was to evaluate survival and recurrence in stage II endometrial cancer in relation to 
uterine risk stratification after LN resection was introduced and all radiotherapy omitted. 
We further aim to identify subgroups of Danish stage II endometrial cancers with favorable 
prognosis by evaluating survival and risk and type of recurrence to help tailor surgery and 
adjuvant therapy for this heterogeneous group of patients.
MATERIALS AND METHODS
The validated Danish Gynecological Cancer Database (DGCD) years 2005–2012 includes 
4,380 radically operated Danish patients with endometrial cancer (excluding sarcomas and 
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carcinosarcomas) [11,12]. Details of the database have been published previously [13] In 
the present study, 708 cases with cervical stromal invasion were included, and of these 461 
were stage II cases. Inclusion of patients is demonstrated in Fig. 1. As FIGO stage (88 to 
2009) changed during the study period, all cases were reclassified to FIGO 2009 using the 
pathology reports [13]. All treatment of endometrial cancer was centralized to 6 centers in 
2010 and all together 528 of the 708 patients with cervical stromal invasion were operated in 
one of the 6 centers (74.6%)
Stage II cases were further divided into original uterine risk group without consideration 
of cervical stromal invasion. Uterine risk groups were defined as follows: 1) low-risk stage 
II: grades 1/2, <50% myometrial invasion, 2) intermediate-risk stage II: grades 1/2, >50% 
myometrial invasion, or grade 3, <50% myometrial invasion), and 3) high-risk stage II: grade 
3, >50% myometrial invasion or non-endometrioid (clear cell, serous, undifferentiated 
carcinoma if >10% of the tumor). Stage II cases were further divided into LN or not LN staged 
and into given and not given EBRT.
The database is validated yearly [11]. Using uniform guidelines, the operating gynecologist 
performed the primary registration of surgery cases with regard to cervical stromal invasion. 
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4,706 endometrial cancer patients 
4,516 hysterectomy
4,380 radically operated
708 cervical stromal invasion stage I–IV
 (OS=64.8)
690 stage II–IIIC
(OS=65.6)
595 stage II–IIIb
(OS=68.7)
527 stage II–IIIa
 (OS=72.4)
461 stage II
 (OS=73.9)
158 stage II low-risk
(OS=91.8)
208 stage II intermediate-risk
(OS=69.6)
95 stage II high-risk
(OS=53.2)
Excluded: 190 not operated
136 not radically operated
18 stage IV
(OS=33.3)
95 stage IIIc (OS=46.3)
77 pelvic LN metastasis (OS=42.9)
18 paraaortic LN metastasis (OS=61.1)
68 stage IIIb (OS=39.7)
 (OS=39.0)
66 stage IIIa
(OS=62.1)
Fig. 1. Number of patients included in the study and the OS of sub-groups. 
LN, lymph node; OS, overall survival.
Stage II case were offered radical hysterectomy type C and also bilateral salpingo-oophorectomy 
when recognized preoperatively. Cervical invasion was recognized preoperatively from biopsy 
of visual tumor on cervix and in few cases by MRI (approximately 30 patients) during 2 Danish 
studies on the ability of MRI to determent stage of endometrial cancer [3,4]. Peritoneal washings, 
intraabdominal assessment and at that time omentectomy were offered to women with serous, 
clear and undifferentiated tumors. Routine pelvic lymphadenectomy was recommended if age 
and comorbidities permitted. No further criteria for omitting lymphadenectomy were specified 
but were left to the surgeon and patient to decide. Some institutions also undertook para-aortic 
lymphadenectomy in high-risk cases. All enlarged nodes were removed.
The pathologists reported according to uniform guidelines described previously [13].
EBRT was recommended for stage II until 2010 (mainly 50 Gy in 27 fractions). Only 40% of 
stage II received radiotherapy before 2010 and 2.8% after 2010. After 2011 stage II patients 
were instead offered participation in the ongoing ENGOT-EN2-DGCG/EORTC-55102 
protocol (a randomized phase 3 trial where effect of postoperative chemotherapy (6 series of 
paclitaxel-carboplatin) is compared with postoperative observation alone (standard strategy) 
[10]. Patients not participating in this study was instead offered 5 years follow-up with no 
further treatment (every 3–6 months for 3–5 years). No cases received brachytherapy.
Missing data in the DGCD and causes of death were retrieved from patients' medical records, 
the Danish Central Person Register, the death register of the Danish National Board of 
Health, and from pathology reports using the Danish pathology database, as described 
previously [13]. All histologically verified recurrences (568) were obtained from the pathology 
database, and another 90 non-histologically verified recurrences identified by checking the 
medical record of patients that had subsequently died.
Medical records were reviewed for patients with known recurrences to retrieve site, time and 
treatment of recurrences, as described previously [9,13]. If a patient had a recurrence in more 
than one location, we also registered the most “severe” first recurrence, defined as the recurrence 
with the lowest cancer-specific survival in the order of distant>abdominal>pelvic>vaginal, to 
enable the determination of isolated vaginal and pelvic recurrences.
Data were analyzed using STATA 11 (StataCorp, College Station, TX, USA) [14]. Kaplan–
Meier estimates and actuarial recurrence rates were used to compute actuarial survival and 
recurrence rates. In all, 5 of 461 stage II patients had left Denmark and were lost to follow-up. 
Recurrence-free survival was estimated using time from surgery to first recurrence, censoring 
patients dying from causes other than endometrial cancer. Student's t-test was used to 
calculate differences between means and Person χ2 for differences between categorical 
parameters. Differences between actuarial survival and recurrence rate in different groups 
were calculated using adjusted Cox regression analysis after adjustment for age (20–59, 
60–69, 70–79, and over 80) American Society of Anesthesiologists comorbidity index (1, 2, 
3–4, and unknown [1/461]), grade (grades 1, 2, 3, or serous, clear, undifferentiated), type of 
hysterectomy (simple, radical, or unknown [25/461]), LN resection (yes/no), and adjuvant 
therapy with EBRT (yes/no) or chemotherapy (yes/no) as categorical parameters.
No approval from The Danish Ethics Committees was needed. The study was approved by 
the Danish Data Protection Board (Journal No. 2010-41-4627) and by the Danish health 
authorities (Journal No. 3-3013-297/1/).
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RESULTS
The mean observation time for survival was 9.0±2.3 years (range, 5.1–13.1) and for 
recurrences at least 60 months. Details of patients included are shown in Table 1 and Fig. 1.
Cervical stromal invasion was present in 17.6% (795/4,516) of all cases that had undergone 
hysterectomy (including 136 cases not radically operated). Of cases with stromal invasion, 
58.0% (461 cases) were stage II.
1. Uterine risk groups
We evaluated whether the uterine risk groups were an independent predictor for overall 
cancer-specific and progression-free survival in final stage II cases by multivariate Cox 
analysis (Table 2) and found uterine risk group to be an independent risk factor for overall 
survival (OS), cancer specific and progression free survival. Uterine risk groups are stronger 
predictor of survivals and recurrences then lymphovascular space invasion (LVSI) and LN 
status. (Table 2)
We further evaluated whether the subdivision of stage II into uterine risk groups would 
have the same predictive value as it does for stage I cases (Table 3 and Fig. 2). For stage II, 
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Table 1. Comparison of epidemiological, surgical, and histological characteristics of patients with II stage endometrial cancer in relation to uterine risk group, 
postoperative external beam radiation and LN resection
Variables All stage II Stage II divided according to uterine risk group LN resection EBRT
Low-risk Intermediate-risk High-risk −LN +LN −RT +RT
Number 461 158 208 95 248 213 344 117
Age (yr) 68.0±10.9 64.6±11.6 69.2*±10.3 70.9*±9.5 68.8±11.3 67.0±10.3 69.2±11.3 64.4*±8.82
ASA 1.77±0.68 1.60±0.7 1.81†±0.66 1.95*±0.66 1.79±0.72 1.74±0.62 1.85±0.69 1.52*±0.58
BMI 27.8±6.29 27.6±6.9 28.4±5.9 27.0±6.0 27.4±6.28 28.3±6.29 27.9±6.26 27.6±6.4
Grade 1 213 (46.2) 107 (67.7) 106§ (51.0) - 127 (51.2) 86§ (40.4) 167 (48.6) 46‡ (39.3)
Grade 2 138 (29.9) 51 (32.3) 87 (41.8) - 82 (33.1) 56 (26.3) 90 (26.2) 48 (41.0)
Grade 3 50 (10.8) - 15 (7.2) 35§ (36.8) 15 (6.1) 35 (16.4) 43 (12.5) 7 (6.0)
Serous, clear, undiff. 60 (13.0) - - 60 (63.2) 24 (9.7) 36 (16.9) 44 (12.8) 16 (13.7)
Deep myometrial invasion 255 (55.3) 0 193* (92.8) 62* (65.3) 130 (52.4) 125 (58.7) 200 (58.1) 55* (47.0)
Cervical glandular involvement 175 (38.0) 41 (26.0) 74† (35.6) 60* (63.2) 90 (36.3) 85 (39.9) 133 (38.7) 42 (35.9)
Endometrioid 401 (87.0) 158 (100) 208 (100) 35* (36.8) 224 (90.3) 177† (83.1) 300 (87.2) 101 (86.3)
Non-endometrioid 60 (13.0) - - 60 (63.2) 24 (9.7) 36 (16.9) 44 (12.8) 16 (13.7)
LVSI of know status 94/299 (31.4) 9/87 (10.3) 62/153§ (40.5) 23/59§ (39.0) 49/152 (32.2) 45/147 (30.6) 69/229 (30.1) 25/70 (35.7)
Unknown LVSI 162 (35.1) 71 (44.9) 55 (26.4) 36 (37.9) 96 (38.7) 66 (31.0) 115 (33.4) 47 (40.2)
Simple hysterectomy 363 (78.7) 127 (80.4) 172 (86.7) 64† (67.4) 236 (95.2) 127§ (59.6) 256 (74.4) 107§ (91.5)
Radical hysterectomy 73 (15.8) 20 (12.7) 25 (12.0) 28 (29.5) 4 (1.6) 69 (32.4) 65 (18.9) 8 (6.8)
Unknown 25 (5.4) 11 (7.0) 11 (5.3) 3 (3.2) 8 (3.2) 17 (8.0) 23 (6.7) 2 (1.7)
Nodal staging 213 (46.2) 56 (35.4) 96* (46.1) 61* (64.2) 0 213* (100) 192 (55.8) 21* (18.0)
Pelvic LN resection 213 (46.2) 56 (35.4) 96 (46.1) 61 (64.2) 0 213* (100) 192 (55.8) 21* (18.0)
Paraaortic LN resection 11 (2.4) 1 (0.6) 4 (1.9) 6 (6.3) 0 11 (5.2) 11 (3.2) 0
No adjuvant therapy 296 (64.2) 100 (63.3) 138 (66.4) 58§ (61.1) 125 (50.4) 171§ (80.3) 296 (86.1) 0§
RT 115 (25.0) 47 (29.8) 49 (23.6) 19 (20.0) 94 (37.9) 21* (9.9) - 115 (98.3)
Chemo 48 (10.4) 10 (6.3) 20 (9.6) 18 (19.0) 27 (10.9) 21 (9.9) 48 (14.0) 0*
RT+Chemo 2 (0.43) 1 (0.6) 1 (0.5) - 2 (0.8) - - 2 (1.7)
Death <5 years 120 (26.0) 13 (8.2) 63* (30.3) 44* (46.3) 75 (30.2) 45† (21.1) 97 (28.2) 23 (19.7)
From cancer 69 (15.0) 6 (3.8) 34* (16.4) 29* (30.5) 41 (16.5) 28 (13.2) 50 (14.5) 19 (16.2)
From others 51 (11.0) 7 (4.4) 29† (13.9) 15† (15.8) 34 (13.7) 17 (8.0) 47 (13.7) 4† (3.4)
Data are shown as mean±standard deviation or number (%).
ASA, American Society of Anesthesiologists; BMI, body mass index; EBRT, external beam radiotherapy; LN, lymph node; LVSI, lymphovascular space invasion; RT, 
radiation therapy; Undiff., undifferentiated.
*p<0.001, †p<0.05 using Student's t-test or χ2 test when intermediate-risk and high-risk were compared to low-risk or RT against no RT or LN resection against 
no LN resection; ‡p<0.001, §p<0.05 using χ2 test distribution when intermediate-risk and high-risk were compared to low-risk or between RT and no RT or LN 
resection and no LN resection.
survival decreased with increasing risk-group, resulting in a 4.0 times lower risk of survival 
for stage II intermediate-risk (adjusted hazard ratio [aHR]=3.99; 95% confidence interval 
[CI]=2.18–7.30; p<0.001) and 7.7 times lower risk of survival for high-risk as compared 
to stage II low-risk (aHR=7.72; 95% CI=4.01–14.9; p<0.001). The risk of both local and 
especially non-local recurrence was significantly higher for both intermediate-risk stage II 
and high-risk stage II as compared to low-risk stage II. We further compared the subdivision 
of stage II with the corresponding stage I risk groups. Survival and recurrence of low-risk 
stage II patients were almost comparable to low-risk stage I patients, except for significantly 
higher locoregional recurrences in stage II low-risk (8.9%) as compared to stage I low-risk 
(4.9%). However, intermediate- and high-risk stage II had decreased cancer-specific survival 
and increased recurrence compared to the corresponding intermediate- or high-risk stage I 
cases (Table 3 and Fig. 2).
LVSI was not included in the risk stratification because LVSI status was unknown in 35% 
of stage II cases. To exclude LVSI as a confounder, we repeated the adjusted Cox analysis 
including LVSI status and found very similar results, except for a non-significant, but higher 
cancer-specific survival in high-risk stage II compared to stage I (p=5.6%).
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Table 2. Predictors of 5-year survival or recurrence of stage II endometrial cancer were calculated for prognostic factors (uterine risk group, LVSI status, and LN 
status) and for treatments factors (type of hysterectomy, LN resection, postoperative EBRT, and chemotherapy) by univariate and multivariate Cox analysis
Variables Overall survival Cancer-specific survival Progression-free survival
No. (%) % (95% CI) HR/aHR  
(95% CI)
% (95% CI) HR/aHR (95% CI) % (95% CI) HR/aHR (95% CI)
Prognostic factors* 461 73.9 (69.6–77.7) 84.1 (80.3–87.2) 76.3 (72.1–80.0)
Uterine risk group
Low-risk 158 91.8 (86.3–95.1) 96.2 (91.6–98.3) 90.5 (84.7–94.1)
Intermediate-risk 208 69.6 (62.9–75.4) 4.17‡/3.60‡  
(1.95–6.65)
82.2 (75.9–86.9) 4.87‡/4.09§  
(1.68–9.98)
73.0 (66.1–78.6) 3.02‡/2.63§  
(1.44–4.79)
High-risk 95 53.2 (42.6–62.7) 7.89‡/6.82‡  
(3.56–13.07)
66.1 (54.9–75.1) 11.26‡/10.41‡  
(4.15–26.11)
58.3 (47.2–67.8) 5.51‡/5.08‡  
(2.68–9.65)
No LVSI 205 77.6 (71.2–82.7) 87.2 (81.6–91.1) 82.0 (75.9–86.7)
LVSI 94 62.8 (52.2–71.7) 1.94§/1.47  
(0.94–2.30)
72.2 (61.4–80.5) 2.46§/1.84‡  
(1.04–3.26)
62.9 (52.0–72.1) 2.41‡/1.93§  
(1.19–3.14)
Unknown LVSI 162 75.7 (68.3–81.6) 1.12/1.08  
(0.70–1.67)
86.8 (80.2–91.3) 1.05/1.02  
(0.56–1.86)
76.6 (69.1–82.6) 1.37/1.38  
(0.86–2.21)
No LN resection 248 69.6 (63.4–74.9) 81.9 (76.2–86.3) 75.9 (69.9–80.9)
Negative LNs 213 78.9 (72.8–83.8) 0.67§/0.60§  
(0.40–0.89)
86.4 (80.9–90.4) 0.76/0.56§  
(0.34–0.94)
76.8 (70.4–82.0) 0.95/0.80  
(0.53–1.20)
Treatment factors†
Simple hysterectomy 363 (78.7) 73.7 (68.9–77.9) 84.4 (80.0–87.8) 76.7 (71.9–80.8)
Radical hysterectomy 73 (15.8) 69.9 (57.9–79.0) 1.13/1.70  
(0.98–2.96)
79.9 (68.4–87.6) 1.29/1.65  
(0.82–3.29)
70.5 (58.4–79.7) 1.27/1.39  
(0.81–2.39)
Unknown type of hysterectomy 25 (5.4) 88.0 (67.3–96.0) 0.42/0.68  
(0.21–2.20)
91.7 (70.6–97.9) 0.51/0.82  
(0.19–3.45)
87.5 (66.1–95.8) 0.49/0.57  
(0.17–1.83)
No LN resection 248 (53.8) 69.6 (63.4–74.9) 81.9 (76.2–86.3) 75.9 (70.0–80.9)
LN resection 213 (46.2) 78.9 (72.8–83.8) 0.67§/0.50§  
(0.31–0.81)
86.4 (80.9–90.4) 0.76/0.53‡  
(0.31–0.99)
76.8 (70.4–82.0) 0.95/0.59§  
(0.36–0.97)
No postoperative EBRT 344 (74.6) 71.7 (66.6–76.1) 84.3 (79.8–87.8) 74.4 (69.3–78.8)
Postoperative EBRT 117 (25.4) 80.3 (71.9–86.5) 0.66/0.66  
(0.39–1.11)
83.4 (75.3–89.1) 1.06/0.89  
(0.47–1.68)
81.7 (73.4–87.7) 0.67/0.47§  
(0.26–0.82)
No postoperative chemotherapy 411 (89.2) 72.9 (68.4–77.0) 83.5 (79.4–86.8) 75.2 (70.6–79.2)
Postoperative chemotherapy 50 (10.9) 81.7 (67.8–90.0) 0.63/0.59  
(0.28–1.23)
88.9 (75.3–95.2) 0.60/0.48  
(0.18–1.27)
85.4 (71.8–92.8) 0.55/0.37§  
(0.17–0.84)
ASA, American Society of Anesthesiologists; aHR, adjusted hazard ratio; CI, confidence interval; EBRT, external beam radiotherapy; HR, hazard ratio; LN, lymph 
node; LVSI, lymphovascular space invasion.
*Adjusted for the other prognostic factors, age, and ASA; †Adjusted for the other treatment factors and age, ASA, grades 1, 2, 3, unfavorable tumor type; 
‡p<0.001, §p<0.05.
As the inclusion of both LN staged and non-staged also could be a bias, we further compared 
the recurrences of the 3 uterine risk groups in staged and non-staged cases. Nevertheless, we 
demonstrated no significant differences between staged and non-staged cases except for a 
significantly lower risk of abdominal recurrences in the intermediate-risk LN staged cases as 
compared to non-staged groups (Fig. 2).
2. LN resection
LNs were removed in 50.1% of all cases with stromal invasion and in 46.2% of stage II 
patients. Examining all radically operated cases with stromal invasion (stage II–IV), the 
removal of LNs in 355 cases diagnosed 27.9% (99 patients: 95 patients stage IIIC and 4 
patients stage IV) with LN metastasis. The risk of LN metastasis at primary surgery increased 
in relation to uterine risk groups (low-risk + stromal invasion: 8.5%, intermediate-risk 
+ stromal invasion: 29.6%, and high-risk + stromal invasion: 36.8%). In all, 18.1% were 
upstaged from stage II to IIIC due to LN metastasis (low-risk: 8.2%, intermediate-risk: 
22.0%, and high-risk: 22.8%), indicating the need for LN staging.
For stage II, the mean±standard deviation [SD] of pelvic LNs was 19.8±10.1 (95% CI=1–52), 
and in the 11 cases with paraaortic LN resection, the mean number was 4.9±3.1 (SD) (range, 
1–11). Groups were not comparable because LN resected stage II patients had significantly 
higher tumor grade, more non-endometrioid tumors, more often radical hysterectomy and 
less postoperative adjuvant therapy than non-staged. Thus, LN-resected stage II cases had 
significantly higher overall, cancer-specific and recurrence-free survival and fewer vaginal and 
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Table 3. Survival and risk of recurrence for II as compared to stage I endometrial cancer after stratification into risk group according to risk factors (grade, 
myometrial invasion, unfavorable tumor types). Two adjusted Cox comparisons were performed 1. Intermediate- or high-risk were compared to low-risk (2 right 
columns) and 2. Stage II with uterine low-, intermediate- and high-risk features were compared to corresponding risk groups of stage I to evaluate whether 
cervical invasion in itself is a risk factor (Differences marked with ‡)
Variables All Uterine risk group HR (95% CI) Compared to low-risk
Low-risk Intermediate-risk High-risk Intermediate-risk High-risk
Stage I 3,426 2,247 873 306
5-year survival
OS 86 (85–87) 91 (89–92) 82 (80–85) 65 (59–70) 1.49* (1.19–1.86) 3.37* (2.55–4.47)
Cancer-specific survival 95 (94–95) 97 (96–98) 94 (92–95) 79 (74–83) 1.49 (0.84–2.67) 6.13* (3.74–10.07)
Recurrence-free survival 90 (89–91) 94 (93–95) 85 (82–87) 73 (68–78) 2.20* (1.69–2.86) 4.41* (3.13–6.22)
Actuarial recurrences <5 years
Locoregional recurrences 7.1 (6.3–8.1) 4.9 (4.1–5.9) 10.8 (8.8–13.1) 14.3 (10.6–19.0) 1.98* (1.46–2.68) 3.19* (2.07–4.91)
Non locoregional recurrences 5.6 (4.9–6.5) 2.5 (1.9–3.3) 8.1 (6.4–10.2) 22.9 (18.4–28.3) 2.85* (1.94–4.20) 8.83* (5.63–13.8)
Pelvic or paraaortic LN recurrences 2.8 (2.3–3.5) 1.2 (0.8–1.8) 4.5 (3.3–6.2) 11.1 (7.8–15.6) 3.09* (1.77–5.37) 7.71* (4.01–14.8)
Non-local LN recurrences 1.3 (0.9–1.7) 0.6 (0.3–1.0) 2.0 (1.2–3.3) 5.5 (3.2–9.3) 3.20† (1.41–7.30) 7.21* (2.66–19.6)
Stage II 461 158 (34.3) 208 (45.1) 95 (20.6)
5-year survival
OS 74‡ (70–78) 92 (86–95) 70‡ (63–75) 53 (43–63) 3.99* (2.18–7.30) 7.72* (4.01–14.9)
Cancer specific-survival 84‡ (80–87) 96 (92–98) 82‡ (76–87) 66§ (55–75) 4.97* (2.07–12.0) 12.5* (5.00–31.5)
Recurrence free-survival 76‡ (72–80) 90§ (85–94) 73‡ (66–79) 58§ (47–68) 3.03* (1.69–5.45) 6.39* (3.34–12.2)
Actuarial recurrences <5 years
Locoregional recurrences 17.9‡ (14.6–21.9) 8.9§ (5.4–14.6) 20.1‡ (15.0–26.6) 30.7‡ (21.8–42.2) 2.35† (1.24–4.43) 4.77* (2.32–9.79)
Non locoregional recurrences 15.4‡ (12.2–19.2) 3.3 (1.4–7.8) 19.7‡ (14.6–26.3) 27.9 (19.4–39.1) 6.54* (2.53–16.9) 11.9* (4.32–33.0)
Pelvic or paraaortic LN recurrences 9.9‡ (7.4–13.3) 2.0 (0.6–6.2) 14.9‡ (10.4–21.0) 13.4 (7.4–23.7) 7.96* (2.37–26.7) 7.34† (1.88–28.6)
Non-local LN recurrences 2.5 (1.4–4.7) 0.7 (0.1–4.7) 3.5 (1.6–7.7) 3.8 (1.2–11.5) 5.42 (0.63–46.8) 9.21 (0.82–103.8)
Survival is given as % (95% CI) and risk of recurrence is given as actuarial recurrences rate in % (95% CI).
aHR is represented adjusted for significant or potential confounders by multivariate analysis including, age, American Society of Anesthesiologists, grade, type 
of hysterectomy, lymph node resection, adjuvant EBRT or chemotherapy. Cox was not adjusted for grades 1, 2, 3, unfavorable tumor types when evaluating risk 
groups as this confounder is also represented in the risk groups.
aHR, adjusted hazard ratio; CI, confidence interval; EBRT, external beam radiotherapy; HR, hazard ratio; OS, overall survival.
*p<0.001, †p<0.05: aHR testing intermediate- or high-risk against low-risk; ‡p<0.001, §p<0.05: aHR testing risk group stage II against corresponding to risk group 
stage I.
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Fig. 2. Five-year actuarial recurrence rates (vaginal, pelvic, abdominal, and distant) for (A) low-, intermediate-, and high-risk stage II compared to 
corresponding stage I risk groups and (B) stage II patients lymph-node staged as compared to non-LN staged. 
LN, lymph node. 
*p<0.05 testing low-, intermediate- and high-risk stage II patients against the corresponding stage I risk group; †p<0.05 using adjusted Cox analysis between 
either stage I or II or between stage II LN resected and not resected.
Table 4. Five-year actuarial recurrence rates for 461 stage II endometrial cancer patients
Variables All stage II LN resection Postoperative radiotherapy
No LN resection LN resection No radiotherapy EBRT
Number 461 248 213 344 117
a) Total recurrence rate 105 (23.6) 57 (24.1) 48 (23.2)† 84 (25.6) 21 (18.2)†
All vaginal 53 (12.4) 30 (12.9) 23 (11.8)† 45 (14.2) 8 (7.3)†
All pelvic 41 (10.1) 20 (9.3) 21 (11.0) 38 (12.7) 3 (2.8)†
All abdominal 37 (9.1) 22 (10.1) 15 (7.9) 27 (9.2) 10 (8.9)
All distant 45 (11.2) 22 (10.7) 23 (11.9) 33 (11.4) 12 (11.0)
b) Site of most severe 1. recurrence
Vaginal 26 (6.2) 16 (6.9) 10 (5.4)† 23 (7.4) 3 (2.8)†
Pelvic 14 (3.6) 7 (3.5) 7 (3.8) 13 (4.5) 1 (1.1)
Abdominal 19 (4.6) 12 (5.4) 7 (3.8) 14 (4.7) 5 (4.5)
Distant 45 (11.2) 22 (10.7) 23 (11.9) 33 (11.4) 12 (11.0)
c) Locoregional LN recurrences 40 (9.9) 21 (9.9) 19 (10.0) 32 (10.9) 8 (7.4)
All PL 29 (7.3) 14 (6.5) 15 (8.1) 27 (9.4) 2 (1.8)
All PA 22 (5.5) 16 (7.7) 6 (3.1)† 14 (4.8) 8 (7.4)
d) Extra abdominal LN 10 (2.5) 6 (3.0) 4 (2.1) 8 (2.8) 2 (1.8)
Values are presented as number (%).
Recurrences were divided into 1. Given or not given RT 2. LN resected or not. Recurrences divided into a) Total recurrence rate: number of recurrences at each 
location: vaginal, pelvic, abdominal, or distant metastasis. If a patient had recurrences at several sites, the patient can be represented more than once, b) 
First recurrence: most serious first recurrence in order of distant>abdominal>pelvic>vaginal, c) Locoregional LN recurrences (pelvic or aortic LN), and d) Extra 
abdominal LN (inguinal, mediastinal, neck, and axillar).
aHR, adjusted hazard ratio; EBRT, external beam radiotherapy; HR, hazard ratio; LN, lymph node; PA, paraaortic lymph nodes; PL, pelvic lymph nodes.
†p <0.05 using aHR: HR/aHR: adjusted for significant or potential confounders by multivariate analysis including age, American Society of Anesthesiologists, 
grades 1, 2, 3, unfavorable tumor types, type of hysterectomy, LN resection, adjuvant EBRT, or chemotherapy.
paraaortic LN recurrences than non-staged (Tables 2 and 4). As these finding may be a result 
of stage migration, survival was also compared including cases upstaged due to LN metastasis 
only (47 cases) to create comparative groups. This demonstrating no significant differences in 
OS (staged including LN metastasis/non-staged 74.2%/69.6%, hazard ratio [HR]=0.79; 95% 
CI=0.52–1.19; p=0.262), cancer-specific (81.3%/81.9%, HR=1.00; 95% CI=0.59–1.68; p=0.229), 
or recurrence-free survival (71.9/75.9%, HR=0.90; 95% CI=0.59–1.40; p=0.665), suggesting that 
LN staging in stage II increased survival, mainly due to stage migration.
3. Adjuvant EBRT or chemotherapy
We further compared stage II given or not given EBRT. Less comorbidity, higher grade, 
deeper myometrial invasion, fewer had radical hysterectomy and LN resection and 
chemotherapy were observed in the group 1 compared to the group 2 (Table 1). The 117 
stage II cases given EBRT had significantly higher recurrence-free survival due to better 
local control (vaginal and pelvic recurrences), with no effect on survival compared to no 
radiotherapy (Tables 2 and 4). Chemotherapy in stage II significantly increased recurrence-
free survival compared to no chemotherapy (Table 2)
4. Radical hysterectomy
Radical hysterectomy was only performed in 15.8% of stage II patients (Table 1). No 
differences in overall, cancer-specific or recurrence-free survival were observed between 
radical and simple hysterectomy (Table 2).
5. Comparison to historical data
We finally compared the results of the present study to prior Danish historical results from 
the time when EBRT was still recommended and LN resection was not performed [9,15]. For 
this comparison we had to create comparative groups by using same FIGO stage (FIGO 88) 
and also include patients upstaged from stage I to IIIC due to LN metastasis only (FIGO 88 
stage IIb was compared to FIGO 2009 stage II including patients upstaged from II to IIIC due 
to LN metastasis only). We found no indication of decreased survival (DEMCA 1998–1999 OS, 
65%; present 2005–2012, 72.0%).
DISCUSSION
In the present study, we demonstrate that uterine risk factors (low-, intermediate-, and 
high-) were the strongest predictors of survival and recurrence in stage II, even stronger than 
LVSI and LN status. Cases with stage II low-risk (grades 1–2, <50% myometrial invasion) 
had a prognosis that was almost comparable to low-risk stage I, whereas for intermediate- 
and high-risk, cervical stromal invasion significantly increased the risk of recurrence and 
decreased cancer-specific survival compared to the corresponding stage I intermediate- or 
high-risk groups. Furthermore, in cases with stromal invasion, pelvic LN staging diagnosed 
27.9% with LN metastasis and upstaged 18.1% from stage II to stage IIIC. LN-resected stage 
II cases had significantly higher overall, cancer-specific, progression-free survival, probably 
due to stage migration. Postoperative EBRT increased recurrence-free survival due to a lower 
number of vaginal and pelvic recurrences with no change in survival, in agreement with 
earlier studies [16-18].
The major strength of the present study is the inclusion of an entire population centralized 
to a few hospitals, high number of cases, and loss of only a few patients to follow-up (5 of 
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461) patients with cervical stromal invasion. Selection bias is a limitation when comparing 
subgroups. Known confounders were controlled for, but unknown confounders cannot be ruled 
out. The lack of histological verification at all locations in cases with multiple recurrences is 
a limitation. Another limitation is that LVSI was not included in the definition of risk groups 
as 35% of cases had unknown LVSI status. Instead we used adjusted Cox analysis to analyze 
the effect of the risk stratification in stage II endometrial cancer on survival and recurrence, 
demonstrating similar results when LVSI status was included as a confounder.
Changing a nationwide strategy by omitting all radiotherapy and introducing LN staging in 
the treatment of stage II endometrial cancer needs to be evaluated. We therefore compared 
the results of the present study to prior Danish historical results from the time when EBRT 
was still recommended and LN resection was not performed, using almost comparative 
groups (including upstaged from II to IIIC), but we found no indication of decreased survival 
(stage II: DEMCA 1998–1999 OS, 65%; present 2005–2012, 72.0%), supporting the Danish 
strategy [15].
As we in the present study demonstrated a very high-risk of recurrences in stage II patients (5-
year recurrence rates: 23.6%), a new strategy for adjuvant treatment needs to be considered. 
The low-risk of non-locoregional recurrences (3.3%) found in low-risk stage II indicates 
that no adjuvant therapy may be needed in this group, while the high-risk of recurrence in 
intermediate- (27%) and high-risk stage II (42%) cases underlines the need for effective 
adjuvant therapy. EBRT or brachytherapy for stage II was demonstrated to reduce local 
recurrences without affecting survival [17,19]. No study has clearly demonstrated a benefit 
of chemotherapy for stage II patients [20], but risk stratification to uterine risk groups has 
not been performed. However, in all 19.7% of intermediate- and 27.9% of high-risk stage II 
cases experienced non-local recurrences demonstrating that postoperative adjuvant systemic 
therapy must be considered.
Therefore LN resection for apparent stage II will upstaged patients that may benefit from 
adjuvant chemotherapy, but will also introduce a high-risk of lymph oedema and so fare 
no randomized studies have demonstrated a survival benefit from a full LN resection [21]. 
Therefore, for future perspective sentinel node may be a new approach to ensure proper 
staging with less harm especially less lymph oedema [22]. The LN-resected stage II patients 
in the intermediate- and high-risk groups still have a very high-risk of developing non-local 
recurrences (distant metastasis, 15%–17%). Tewari et al demonstrated that chemotherapy 
to stage III and IV patients with stromal invasion increased OS and PFS as compared to 
whole abdominal irradiation [23], but whether adjuvant therapy is a benefit in stage II 
patients awaits futures studies. The result of the ENGOT-EN2-DGCG/EORTC-55102 trial 
is pending and may add knowledge to the effect of chemotherapy in stage II patients [10]. 
Future research should focus on finding new treatment targets with the potential of reducing 
the risk of non-local recurrences and on the use biomarkers to differentiate between the 
very different characteristics (uterine risk group, histological tumor types, and molecular 
differences) seen in patients with stage II endometrial cancer [24].
In conclusion, in stage II endometrial cancers patients' uterine risk groups are strong 
predictors for survival and recurrence and should be considered when advising adjuvant 
therapy. LN staging for stage II endometrial cancers increases overall and cancer-specific 
survival probably due to stage migration. Omitting radiotherapy increases local vaginal 
recurrences without affecting survival.
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